App-Based Program for Anxiety and Depression

Overseen By Ulrich Kirk, PhD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: University of Southern Denmark

Must be taking: Anxiety, Depression medications

Disqualifiers: Schizophrenia, Psychosis, Bipolar, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: 2

Duration: 3 weeks

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial explores a new Headspace app designed to help manage anxiety and depression using techniques from cognitive behavioral therapy (CBT) and mindfulness. The researchers aim to determine the app's effectiveness in reducing symptoms of anxiety and depression compared to not using it. The trial includes two groups: one using the app and another on a waitlist. Individuals who often feel anxious or depressed, are on stable medication, and have a smartphone might be a good fit for this trial. As an unphased trial, this study offers a unique opportunity to contribute to innovative mental health solutions.

Will I have to stop taking my current medications?

The trial requires that if you are on medication for anxiety or depression, you must have been on a stable dose for at least 4 weeks before starting. If you meet this condition, you can continue your current medications.

What prior data suggests that this app-based program is safe for treating anxiety and depression?

Earlier research has shown that using apps to help with anxiety and depression is safe and effective. Studies indicate that these apps can significantly reduce symptoms of both conditions. A review of 13 studies involving 1,470 participants found that people generally handle app interventions well.

Other research also shows positive results. For instance, after using a similar app for six weeks, participants experienced a significant reduction in anxiety symptoms. These findings suggest that the treatment is safe and can improve mental health without major side effects.

In summary, app-based programs for anxiety and depression have been studied and found to be safe and effective in reducing symptoms. The evidence supports their use for individuals seeking to manage anxiety and depression through digital tools. ^{1 2 3 4 5}

Why are researchers excited about this trial?

Researchers are excited about the App-Based Program for Anxiety and Depression because it offers a new way to manage these conditions through digital means. Unlike traditional treatments like medication and therapy sessions, this program provides a convenient, on-the-go option that can be accessed anytime via a smartphone. This approach has the potential to increase accessibility and consistency in treatment, especially for individuals who may have difficulty attending regular therapy sessions. Additionally, the program could provide personalized feedback and track progress in real-time, offering users a more tailored and interactive experience.

What evidence suggests that this app-based program is effective for anxiety and depression?

Research shows that app-based programs can help reduce anxiety and depression symptoms. In this trial, participants will either use the Anxiety/Depression Program or join a waitlist. A review of studies has found that mobile health apps significantly improve these symptoms, with a moderate level of effectiveness. Another study found that users felt better after using an app for six weeks. These programs often use cognitive behavioral therapy (CBT) and mindfulness techniques, which have proven effective in traditional therapy. Apps make it easier and cheaper for people to access these therapies, helping to overcome common barriers to mental health treatment. ^{2 6 7 8 9}

Who Is on the Research Team?

Ulrich Kirk, PhD

Principal Investigator

University of Southern Denmark

Are You a Good Fit for This Trial?

This trial is for adults with elevated anxiety or depression. Participants should have symptoms of these conditions but not be currently receiving treatment. It's not specified who can't join, so generally those with other mental health treatments or conflicting conditions may be excluded.

Inclusion Criteria

Based in the U.S.

Access to a smartphone device, as the intervention will be delivered via a smartphone application

I have been on a stable dose of anxiety or depression medication for at least 4 weeks.

Exclusion Criteria

I do not have severe mental health issues, serious physical health concerns requiring surgery soon, a prognosis of less than 6 months, or am not pregnant.

Risks associated with suicidal ideation and risk of self-harm

I have not been on a stable dose of medication for anxiety or depression for at least 4 weeks.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

1 visit (virtual)

Treatment

Participants engage in a 3-week app-based intervention or waitlist control

3 weeks

Weekly virtual check-ins

Follow-up

Participants complete a follow-up assessment 3 weeks after the intervention

3 weeks

1 visit (virtual)

What Are the Treatments Tested in This Trial?

Interventions

• Anxiety/Depression Program

Trial Overview The study tests a guided app-based program by Headspace that combines cognitive behavioral therapy (CBT) and mindfulness to treat anxiety and depression. Participants will either use the app or be on a waitlist for comparison over a period of 3 weeks, followed by another 3-week assessment.

How Is the Trial Designed?

Group I: Waitlist Experimental Treatment 1 Intervention

Group II: Anxiety/Depression Program Active Control 1 Intervention

Who Is Running the Clinical Trial?

University of Southern Denmark

Lead Sponsor

Trials

574

Recruited

4,459,000+

Virginia Polytechnic Institute and State University

Collaborator

Trials

162

Recruited

26,900+

Published Research Related to This Trial

The 16-week Feel Program, a digital mental health support initiative, showed a 65% retention rate among 48 adult participants, with high user satisfaction (65% reported very high satisfaction) and significant engagement in activities designed to manage depressive and anxiety symptoms.

Results indicated that 93.5% of participants experienced a decrease in depressive or anxiety symptoms, with 51.6% showing clinically significant improvement, suggesting that higher engagement in the program correlates with better mental health outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Feasibility, engagement, and preliminary clinical outcomes of a digital biodata-driven intervention for anxiety and depression. Tsirmpas, C., Andrikopoulos, D., Fatouros, P., et al.[2022]

The EVAD tool was developed to evaluate and classify the severity of adverse events in psychotherapeutic clinical trials, filling a gap in the existing frameworks for such evaluations.

Content validation showed strong agreement among experts, with perfect scores for relevance and high scores for clarity and coherence, indicating that EVAD is a reliable and meaningful tool for assessing adverse events.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Development and content validity of EVAD: A novel tool for evaluating and classifying the severity of adverse events for psychotherapeutic clinical trials. Mejía-Castrejón, J., Sierra-Madero, JG., Belaunzarán-Zamudio, PF., et al.[2023]

A systematic review of 115 psychotherapy study protocols revealed that while 77 protocols explicitly addressed harm, there was a lack of standardization in how harm was conceptualized and assessed, particularly regarding adverse events.

The review highlighted that although serious adverse events were defined consistently, the definitions and considerations for adverse events varied widely, suggesting a need for more standardized approaches in clinical research to effectively monitor and report harm.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Defining and assessing adverse events and harmful effects in psychotherapy study protocols: A systematic review. Klatte, R., Strauss, B., Flückiger, C., et al.[2023]

A review of 3,278 mobile apps for anxiety disorders in Brazil found that only 71 met the eligibility criteria, with most apps focusing on education, self-assessment, and meditation, but only 43.66% were rated as having acceptable quality according to the Mobile App Rating Scale (MARS).

There was a notable discrepancy between user star ratings and the quality assessed by MARS, indicating that users should be cautious when selecting these apps for managing anxiety disorders, as many apps were classified as low quality.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Evaluation of mobile applications focused on the care of patients with anxiety disorders: A systematic review in app stores in Brazil. Souza do Nascimento, V., Teotonio Rodrigues, A., Rotta, I., et al.[2023]

The study involving 594 patients showed that implementing computerized outcome feedback (OF) technology in therapy for depression and anxiety did not significantly change clinical outcomes, as measured by PHQ-9 and GAD-7 scores, compared to traditional methods.

However, the use of OF led to a significant reduction in the average duration and cost of treatment, suggesting that OF can enhance the efficiency of stepped care psychological services.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Improving the efficiency of psychological treatment using outcome feedback technology. Delgadillo, J., Overend, K., Lucock, M., et al.[2018]

Current clinical trials for behavioral health interventions often do not monitor adverse events as thoroughly as those for medications and medical devices, focusing mainly on serious incidents like suicide attempts and hospitalizations.

There is a need for expanded monitoring of adverse events in psychotherapy trials to better inform patients about potential risks, including temporary increases in anxiety, which are often overlooked but can impact treatment outcomes.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The need for expanded monitoring of adverse events in behavioral health clinical trials. Peterson, AL., Roache, JD., Raj, J., et al.[2012]

In a systematic review of 117 studies on psychosocial interventions for childhood mental disorders, only 31% monitored adverse events, highlighting a significant gap in safety reporting.

Among the studies that did monitor adverse events, there was a lack of consistency in how these events were defined and assessed, with only 11% evaluating the causes of the events, which is crucial for understanding the risks associated with these treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Review: Adverse event monitoring and reporting in studies of pediatric psychosocial interventions: a systematic review. Lodewyk, K., Bagnell, A., Courtney, DB., et al.[2023]

A digital mental health program providing internet-based cognitive behavioral therapy (iCBT) was successfully implemented in primary care, with 2,228 patients prescribed the program and nearly 49% enrolling, indicating good acceptance among patients.

Patients who engaged with the iCBT program showed significant clinical improvements, with a 23% reduction in depression scores (PHQ-9) and a 26% reduction in anxiety scores (GAD-7), demonstrating the efficacy of digital tools in treating mental health conditions.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Addressing depression and behavioral health needs through a digital program at scale. Sharif-Sidi, Z., Shen, C., Wong, W., et al.[2021]

A systematic review of 22 studies over the past decade found that mobile applications significantly improve symptoms of depression and anxiety, demonstrating their effectiveness as a digital treatment tool.

Mobile apps promote patient empowerment and health literacy, suggesting they can enhance self-management of mental health conditions, but further research is needed to fully integrate them into healthcare practices.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Technological prescription: evaluation of the effectiveness of mobile applications to improve depression and anxiety. Systematic review. Planas, R., Yuguero, O.[2021]

A systematic review identified eight studies of internet-based programs for treating anxiety and depression in children and adolescents, with most interventions based on cognitive behavior therapy.

Six out of eight studies reported reductions in symptoms of anxiety and/or depression after the interventions, indicating early support for the effectiveness of these online programs, although more rigorous research is needed to confirm these findings.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Review of internet-based prevention and treatment programs for anxiety and depression in children and adolescents. Calear, AL., Christensen, H.[2022]

In a study of 260 chronically depressed patients, those receiving Cognitive Behavioral Analysis System of Psychotherapy (CBASP) reported more severe adverse events compared to those receiving supportive psychotherapy, particularly in personal and occupational life.

However, CBASP was associated with fewer adverse events related to suicidal thoughts, suggesting that while it may lead to some temporary challenges, it can be a safer option in terms of suicidal ideation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Adverse events during a disorder-specific psychotherapy compared to a nonspecific psychotherapy in patients with chronic depression. Meister, R., Lanio, J., Fangmeier, T., et al.[2021]

Citations

1. samhsa.gov samhsa.gov/

Home | SAMHSA - Substance Abuse and Mental Health ... SAMHSA leads efforts to advance behavioral health across the U.S., offering resources for mental health, substance use, and community well-being.

2. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC9494214/

Systematic Review and Meta-Analysis - PMC - PubMed Central We conducted a systematic review and meta-analysis to evaluate the dose effectiveness of app-based mHealth interventions for anxiety and depression symptom ...

3. mhealth.jmir.org mhealth.jmir.org/2020/7/e15418/

Effectiveness of a Mobile App Intervention for Anxiety and ... We found preliminary evidence that the Feel Stress Free app reduced depression and anxiety symptoms after 6 weeks. At secondary time points, we ...

4. nature.com nature.com/articles/s41746-025-01860-3

Transdiagnostic-focused apps for depression and anxiety This meta-analysis evaluated the efficacy of transdiagnostic-focused apps for depression and anxiety, and aimed to understand how they compare to diagnostic- ...

5. jamanetwork.com jamanetwork.com/journals/jamanetworkopen/fullarticle/2812076

App-Based Interventions for Moderate to Severe Depression This systematic review and meta-analysis of 13 randomized clinical trials of app interventions with 1470 participants found a significant medium effect size ...

6. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC10660171/

App-Based Interventions for Moderate to Severe Depression This systematic review and meta-analysis of 13 randomized clinical trials of app interventions with 1470 participants found a significant medium effect size ...

7. jamanetwork.com jamanetwork.com/journals/jamanetworkopen/fullarticle/2822451

Efficacy of a Mobile App-Based Intervention for Young ... However, after 6 weeks of use of the app, there was a clinically and statistically significant decrease in anxiety symptoms across conditions.

8. pmc.ncbi.nlm.nih.gov pmc.ncbi.nlm.nih.gov/articles/PMC7240649/

Coached Mobile App Platform for the Treatment of ... The rate of recovery from anxiety was 56.9% in IntelliCare and 37.9% in WLC. The odds of recovery for depression were 3.25 (95% CI, 1.54-6.86) ...

9. nature.com nature.com/articles/s41746-021-00386-8

Smartphone apps for depression and anxiety: a systematic ... Meta-analyses have shown that digital mental health apps can be efficacious in reducing symptoms of depression and anxiety.